Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Ernexa Therapeutics announced progress on its lead cell therapy candidate ERNA-101, designed to transform immunologically 'cold' ovarian tumors into tumors recognizable by the immune system. The company plans to submit an IND in Q3 2026 and start a first-in-human Phase 1 study in Q4 2026. Preclinical data shows promising results including complete …